A new score combining compound muscle action potential (CMAP) amplitudes and motor score is predictive of motor outcome after AVXS-101 (Onasemnogene Abeparvovec) SMA therapy

[1]  S. Mercier,et al.  Fatal thrombotic microangiopathy case following adeno-associated viral SMN gene therapy , 2022, Blood advances.

[2]  F. Heinen,et al.  Quantitative Motion Measurements Based on Markerless 3D Full-Body Tracking in Children with SMA Highly Correlate with Standardized Motor Assessments. , 2021, Journal of neuromuscular diseases.

[3]  B. Chabrol,et al.  Motor unit number index: A potential electrophysiological biomarker for pediatric spinal muscular atrophy , 2021, Muscle & nerve.

[4]  R. Finkel,et al.  Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial , 2021, The Lancet Neurology.

[5]  D. Kariyawasam,et al.  Motor unit changes in children with symptomatic spinal muscular atrophy treated with nusinersen , 2020, Journal of Neurology, Neurosurgery, and Psychiatry.

[6]  A. Ziegler,et al.  European ad-hoc consensus statement on gene replacement therapy for spinal muscular atrophy , 2020, European Journal of Paediatric Neurology.

[7]  M. Ryan,et al.  Biomarkers and the Development of a Personalized Medicine Approach in Spinal Muscular Atrophy , 2019, Front. Neurol..

[8]  Markus Weber,et al.  Motor Unit Number Index (MUNIX) of hand muscles is a disease biomarker for adult spinal muscular atrophy , 2019, Clinical Neurophysiology.

[9]  J. Mendell,et al.  AVXS-101 (Onasemnogene Abeparvovec) for SMA1: Comparative Study with a Prospective Natural History Cohort. , 2019, Journal of neuromuscular diseases.

[10]  Craig McDonald,et al.  Natural history of infantile‐onset spinal muscular atrophy , 2017, Annals of neurology.

[11]  Brian K. Kaspar,et al.  Single‐Dose Gene‐Replacement Therapy for Spinal Muscular Atrophy , 2017, The New England journal of medicine.

[12]  R. J. Ramamurthi,et al.  Nusinersen versus Sham Control in Infantile‐Onset Spinal Muscular Atrophy , 2017, The New England journal of medicine.

[13]  D. Vissière,et al.  P.429 Innovative home activity monitoring in non-ambulant patients with spinal muscular atrophy: a multicenter observational trial , 2017, Neuromuscular Disorders.

[14]  N. Vayatis,et al.  An Automated Recording Method in Clinical Consultation to Rate the Limp in Lower Limb Osteoarthritis , 2016, PloS one.

[15]  J. Kissel,et al.  Spinal Muscular Atrophy. , 2015, Neurologic clinics.

[16]  W. Chung,et al.  Observational study of spinal muscular atrophy type I and implications for clinical trials , 2014, Neurology.

[17]  W. Chung,et al.  The motor neuron response to SMN1 deficiency in spinal muscular atrophy , 2014, Muscle & nerve.

[18]  Xiaobai Li,et al.  Electrophysiological biomarkers in spinal muscular atrophy: proof of concept , 2013, Annals of clinical and translational neurology.

[19]  M. Schroth,et al.  Compound muscle action potential and motor function in children with spinal muscular atrophy , 2010, Muscle & nerve.

[20]  Mark B Bromberg,et al.  Natural history of denervation in SMA: Relation to age, SMN2 copy number, and function , 2005, Annals of neurology.